We currently screen for 4 major cancers with guideline-backed tools. Yet ~70% of cancer deaths come from cancers without routine screening. That’s the gap MCED testing is trying to close. CancerGuard is a multi-cancer early detection (MCED) blood test developed by the team behind Cologuard®. It analyzes circulating tumor DNA (ctDNA) plus protein biomarkers to detect cancer-associated signals across multiple organ systems. 🔍 What It Screens For CancerGuard evaluates signals associated with 50+ cancer types and subtypes, including: - Lung - Pancreatic - Hepatobiliary - Gastric & esophageal - Ovarian - Renal - Bladder - Head & neck - Select hematologic malignancies It is not intended to replace: - Mammography - Colonoscopy/FIT - Pap/HPV screening - LDCT lung screening in high-risk patients And it does not position itself as a primary screening tool for breast or prostate cancer. This is additive screening — not substitution. It has high specificity over all leading to minimal false positives. But negative results is not a rule out! 📊 Performance Characteristics (Development Data) Here’s the part you actually care about: - Overall sensitivity: ~64% across cancers detected in development studies - Specificity: ~97% - Stage I–II detection: ~1/3 of detected cancers Translation: Sensitivity varies by tumor type and stage (as expected). Performance is stronger in higher-stage disease and certain solid tumors. Specificity is high, which matters when you’re deploying this in asymptomatic populations. False positives are relatively low, but not negligible. This means workflow planning matters. 🧠 Clinical Positioning Intended population: - Age 50–84 - No active cancer within 3 years - Average risk or elevated concern patients - Used in conjunction with standard screening Cost: ~ $689 (cash-pay; HSA/FSA eligible) This is not currently a USPSTF-endorsed screening modality. 🏥 Practical Workflow Considerations Let’s be honest. The value of any screening test is not just sensitivity — it’s system integration.

*🔎 “What if your annual health check could see the cancers no one else checks for?” That’s the idea behind CancerGuard™ — the first multi-cancer early detection blood test that casts a wider net than traditional screening. 🧬 What It Actually Checks CancerGuard isn’t one cancer test — it’s a 50+ cancer signal detector from a single blood draw. Think of it as a broad-spectrum radar for unusual DNA/protein signals that cancers shed into the bloodstream. Here’s the real deal: 🎯 Lung & bronchus cancers 🎯 Pancreatic cancer 🎯 Liver & bile duct cancers 🎯 Stomach & esophageal cancers 🎯 Ovarian cancer 🎯 Kidney & bladder cancers 🎯 Head & neck cancers…and more. It may detect signals for breast or prostate cancer, but it’s not meant to replace standard screening for those. 📊 Here’s what the science says: • Detects signals in ~64 % of cancers in development studies • ~97 % specificity — so false positives are low • Finds ~1/3 of cancers early (Stage I/II) when outcomes are better • Models suggest combined with guideline screening, this could mean fewer late-stage diagnoses and fewer deaths over time 📅 How It Fits With Your Screening The CDC still recommends screenings: ✔ Mammograms (or other screening modality of choice) ✔ Colonoscopy/Cologuard or annual FIT tests ✔ Pap/HPV testing ✔ Lung CT if you qualify Those tests catch cancers where we have proven recommendations. CancerGuard is additional insight — especially for cancers that don’t yet have routine screening tools. Who it’s for: • Adults 50–84 • No active cancer diagnosis in the last 3 years • Want more early detection insight 🧠 What a Result Means: this is a little tricky... 🟥 Positive signal: Something unusual showed up — not a diagnosis by itself. It means we need targeted follow-up with imaging or specialist evaluation. 🟩 Negative: Lowers likelihood, but doesn’t guarantee no cancer. You still keep up with guideline screenings. 💡 Giving it to you straight.... CancerGuard gives you a broader view than traditional screening — almost like moving from a flashlight to a radar sweep. It’s not perfect, and it’s not a replacement, but it’s the biggest leap in early detection coverage we’ve had in decades and affordable in comparison to previous available metrics.